Expression of apoptosis‐related proteins, p53, and DNA fragmentation in sarcomas of the pulmonary artery

Apoptosis is a common feature in a variety of pathologic conditions. Induction of apoptosis through apoptotic stimuli such as, chemotherapy or radiation, presents new insights into tumor biology and therapy. In particular, members of the Bcl‐2 family as well as the Fas system are known to be involved in the regulation of apoptosis in different tumor entities.

[1]  G. Sirera,et al.  Absence of Fas (CD95) and FasL (CD95L) immunohistochemical expression suggests Fas/FasL‐mediated apoptotic signal is not relevant in cutaneous Kaposi's sarcoma lesions , 1999, Journal of cutaneous pathology.

[2]  J. Trapani,et al.  BCL-2 Blocks Perforin-induced Nuclear Translocation of Granzymes Concomitant with Protection against the Nuclear Events of Apoptosis* , 1999, The Journal of Biological Chemistry.

[3]  Y. Yamazaki,et al.  Characteristics of mutations in the p53 gene of oral squamous‐cell carcinomas associated with betel‐quid chewing in Sri Lanka. Int. J. Cancer 77, 839–842 (1998) , 1999, International journal of cancer.

[4]  S. Hirohashi,et al.  Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma , 1999, Oncogene.

[5]  K. Vousden,et al.  Cell cycle arrest and DNA endoreduplication following p21Waf1/Cip1 expression , 1998, Oncogene.

[6]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[7]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[8]  S. H. Kim,et al.  Immunohistochemical analysis of Fas ligand expression in sarcomas. Sarcomas express high level of FasL in vivo , 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[9]  Michael Weller,et al.  Predicting response to cancer chemotherapy: the role of p53 , 1998, Cell and Tissue Research.

[10]  B. Vicandi,et al.  Cytologic features of synovial sarcoma with emphasis on the monophasic fibrous variant , 1998, Cancer.

[11]  R. Iggo,et al.  High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay , 1997, Oncogene.

[12]  I. Park,et al.  Expression of a novel Bcl-2 related gene, Bfl-1, in various human cancers and cancer cell lines. , 1997, Anticancer research.

[13]  P. Walker,et al.  Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. , 1997, Journal of immunology.

[14]  R. Greil,et al.  Expression of Apo‐1/Fas (CD95), Bcl‐2, Bax and Bcl‐x in myeloma cell lines: relationship between responsiveness to anti‐Fas mab and p53 functional status , 1997, British journal of haematology.

[15]  T. Ochi,et al.  Immunohistochemical detection of bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: their correlations with prognosis. , 1997, Oncology.

[16]  P. Galle,et al.  Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.

[17]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[18]  S. Nagata.  Fas‐induced apoptosis, and diseases caused by its abnormality , 1996, Genes to cells : devoted to molecular & cellular mechanisms.

[19]  F. Shanahan,et al.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.

[20]  R. Chetty,et al.  The immunoexpression of bcl‐2 and p53 in Kaposi’s sarcoma , 1996, Histopathology.

[21]  E. van Marck,et al.  Prognostic value of bcl-2 expression in invasive breast cancer. , 1995, British Journal of Cancer.

[22]  A. Strasser,et al.  Bcl-2 and thermotolerance cooperate in cell survival. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[23]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[24]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[25]  A. D. Dei Tos,et al.  Ultraviolet-induced p53 mutations in atypical fibroxanthoma. , 1994, The American journal of pathology.

[26]  John Calvin Reed,et al.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.

[27]  G. Broggi,et al.  p53 mutations and microsatellite analysis of loss of heterozygosity in malignant gliomas. , 1994, Cancer genetics and cytogenetics.

[28]  D. Lane,et al.  p53 In tumour pathology: Can we trust immunohistochemistry?—revisited! , 1994, The Journal of pathology.

[29]  John Calvin Reed,et al.  Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. , 1993, Cancer research.

[30]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[31]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[32]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[33]  S. Hirohashi,et al.  Application of the p53 Gene Mutation Pattern for Differential Diagnosis of Primary Versus Metastatic Lung Carcinomas , 1993, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[34]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[35]  A. Harris,et al.  Increased expression of mutant forms of p53 oncogene in primary lung cancer , 1990, The Lancet.

[36]  Y. Nakanuma,et al.  PRIMARY PULMONARY ARTERY SARCOMA. Report of Two Autopsy Cases Studied by Immunohistochemistry and Electron Microscopy, and Review of 110 Cases Reported in the Literature , 1988, Acta pathologica japonica.

[37]  J. Coindre,et al.  Histopathologic grading in spindle cell soft tissue sarcomas , 1988, Cancer.

[38]  E. Speel,et al.  Gains of 12q13–14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery , 2000, Virchows Archiv.

[39]  M. Greene,et al.  Fas- and perforin-lndependent mechanism of cytotoxic T lymphocyte , 1998, Immunologic research.

[40]  J. Houghton,et al.  Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status. , 1998, Oncology research.

[41]  C. Mothersill,et al.  Expression of delayed toxicity and lethal mutations in the progeny of human cells surviving exposure to radiation and other environmental mutagens. , 1998, International journal of radiation biology.

[42]  P. Shaw,et al.  The role of p53 in cell cycle regulation. , 1996, Pathology, research and practice.

[43]  Thierry Soussi,et al.  P53 Gene Mutation: Software and Database , 1996, Nucleic Acids Res..

[44]  D. de Jong,et al.  Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. , 1994, Cancer research.